Key statistics
As of last trade Innate Pharma SA (IDD:FRA) traded at 1.51, 6.92% above its 52-week low of 1.42, set on Nov 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.51 |
---|---|
High | 1.51 |
Low | 1.51 |
Bid | 1.51 |
Offer | 1.55 |
Previous close | 1.57 |
Average volume | 446.44 |
---|---|
Shares outstanding | 80.97m |
Free float | 60.70m |
P/E (TTM) | -- |
Market cap | 123.72m EUR |
EPS (TTM) | -0.4215 EUR |
Data delayed at least 15 minutes, as of Nov 22 2024 07:01 GMT.
More ▼
- Innate Pharma Releases Its 2025 Financial Calendar
- Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501
- Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results
- Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024
- Innate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates
- Innate Pharma Announces Its Participation in Upcoming Investor Conferences
- Innate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board
- Innate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024
- Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors
- Innate Pharma Reports First Half 2024 Business Update and Financial Results
More ▼